Welcome to our dedicated page for Stryker SEC filings (Ticker: SYK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Stryker Corporation (NYSE: SYK) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that describe Stryker’s financial condition, governance and material events as a global medical technologies company focused on MedSurg, Neurotechnology and Orthopaedics.
Current reports (Form 8-K) play a central role in Stryker’s disclosure practices. For example, the company has filed 8-Ks to furnish press releases announcing second and third quarter 2025 operating results, detailing net sales, segment performance and earnings metrics. Another Form 8-K dated December 4, 2025 reports leadership changes, including the appointment of a President and Chief Operating Officer and a new Group President, Orthopaedics, and summarizes related compensation arrangements.
Through its SEC filings, Stryker also identifies its registered securities and capital structure. Filings list the company’s common stock, traded on the New York Stock Exchange under the symbol SYK, along with multiple series of senior unsecured notes with different maturities that are also listed on the NYSE. These disclosures help investors understand the instruments available for investing in Stryker and the company’s obligations under its notes.
On Stock Titan, Stryker’s filings are updated in step with new submissions to the SEC’s EDGAR system. AI-powered tools summarize key points from lengthy documents, helping readers quickly identify items such as results of operations, leadership changes, segment commentary and descriptions of registered securities. Users can review Stryker’s historical and recent filings to track how the company reports on its MedSurg, Neurotechnology and Orthopaedics businesses, financial performance and governance over time.
Stryker Corp (SYK) Form 4: VP & Chief Communications Officer Kimberly Ann Montagnino had 155 common shares withheld on 01-Aug-2025 (transaction code “F”) at $392.73 to cover tax liabilities on vested equity. Post-withholding, the executive still owns 1,195 shares directly and 13 shares indirectly through a 401(k). No derivative positions or additional trades were reported, and the filing does not cite a Rule 10b5-1 trading plan. Given the small size and tax-related nature, this insider activity is considered routine and unlikely to influence SYK’s valuation.